Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4741135
Max Phase: Preclinical
Molecular Formula: C39H51N9O9S
Molecular Weight: 821.96
Molecule Type: Unknown
Associated Items:
ID: ALA4741135
Max Phase: Preclinical
Molecular Formula: C39H51N9O9S
Molecular Weight: 821.96
Molecule Type: Unknown
Associated Items:
Canonical SMILES: N=C(N)Nc1cc(NC(=O)CCCC(=O)NC23CC4CC(CC(C4)C2)C3)cc(C(=O)NCC(=O)NC[C@H](NC(=O)[C@@H]2CCCN2S(=O)(=O)c2ccccc2)C(=O)O)c1
Standard InChI: InChI=1S/C39H51N9O9S/c40-38(41)45-28-16-26(15-27(17-28)44-32(49)9-4-10-33(50)47-39-18-23-12-24(19-39)14-25(13-23)20-39)35(52)43-22-34(51)42-21-30(37(54)55)46-36(53)31-8-5-11-48(31)58(56,57)29-6-2-1-3-7-29/h1-3,6-7,15-17,23-25,30-31H,4-5,8-14,18-22H2,(H,42,51)(H,43,52)(H,44,49)(H,46,53)(H,47,50)(H,54,55)(H4,40,41,45)/t23?,24?,25?,30-,31-,39?/m0/s1
Standard InChI Key: GFTVRPWYQDITLC-MVBWARRXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 821.96 | Molecular Weight (Monoisotopic): 821.3530 | AlogP: 1.45 | #Rotatable Bonds: 17 |
Polar Surface Area: 282.08 | Molecular Species: ZWITTERION | HBA: 9 | HBD: 9 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.03 | CX Basic pKa: 9.04 | CX LogP: -1.66 | CX LogD: -1.67 |
Aromatic Rings: 2 | Heavy Atoms: 58 | QED Weighted: 0.08 | Np Likeness Score: -1.14 |
1. Sundaram A,Chen C,Isik Reed N,Liu S,Ki Yeon S,McIntosh J,Tang YZ,Yang H,Adler M,Beresis R,Seiple IB,Sheppard D,DeGrado WF,Jo H. (2020) Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness., 30 (22): [PMID:33007395] [10.1016/j.bmcl.2020.127578] |
Source(1):